Children aged 6 to 23 months who receive trivalent inactivated flu vaccine concurrently with the 13-valent pneumococcal conjugate vaccine are at increased risk of febrile seizures, according to researchers at the Centers for Disease Control and Prevention in Atlanta and Harvard Medical School in Boston.
Children aged 6 to 23 months who receive trivalent inactivated flu vaccine (TIV) concurrently with the 13-valent pneumococcal conjugate vaccine (PCV13) are at increased risk of febrile seizures, according to researchers at the Centers for Disease Control and Prevention (CDC) in Atlanta and Harvard Medical School in Boston.
Frank DeStefano, MD, MPH, from the CDC’s Immunization and Safety Office, and Grace M. Lee, MD, MPH, from Harvard Medical School, presented their findings at a recent meeting of the CDC’s Advisory Committee on Immunization Practices (ACIP) in Atlanta. Dr DeStefano noted that fever after vaccination is common and might increase the risk of febrile seizures. He estimated that TIV and PCV13 when given concurrently may account for about 60 seizures per 100,000 children and that such seizures typically occur the day after vaccination.
Unless administered concurrently with PCV13, the 2010/2011 TIV used in the United States is not associated with an increased risk of febrile seizures in children aged 6 to 23 months based on preliminary results from the Vaccine Safety Datalink.
Dr DeStefano put these findings into perspective. “Febrile seizures associated with vaccine administration are associated with a good prognosis, although they can scare parents and caregivers,” he said.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More